Postbiotics in Metabolic Disorders

Β· Β· Β·
Β· CRC Press
αžŸαŸ€αžœαž—αŸ…β€‹αž’αŸαž‘αž·αž…αžαŸ’αžšαžΌαž“αž·αž…
196
αž‘αŸ†αž–αŸαžš
αž˜αžΆαž“αžŸαž·αž‘αŸ’αž’αž·
αž€αžΆαžšαžœαžΆαž™αžαž˜αŸ’αž›αŸƒ αž“αž·αž„αž˜αžαž·αžœαžΆαž™αžαž˜αŸ’αž›αŸƒαž˜αž·αž“αžαŸ’αžšαžΌαžœαž”αžΆαž“αž•αŸ’αž‘αŸ€αž„αž•αŸ’αž‘αžΆαžαŸ‹αž‘αŸ αžŸαŸ’αžœαŸ‚αž„αž™αž›αŸ‹αž”αž“αŸ’αžαŸ‚αž˜

αž’αŸ†αž–αžΈαžŸαŸ€αžœαž—αŸ…β€‹αž’αŸαž‘αž·αž…αžαŸ’αžšαžΌαž“αž·αž€αž“αŸαŸ‡

This book discusses the role of postbiotics in human health. The initial chapter highlights the potential of postbiotics beyond traditional prebiotics and probiotics. Subsequent chapters present the beneficial effects on various health conditions, including cardiovascular disorders, cancer, diabetes, gestational diabetes, obesity, and mitochondrial disorders.

The book covers the role of postbiotics in immune system modulation and inflammation-mediated metabolic disorders. It also explores the interaction of postbiotics with gut microbiota, detailing molecular mechanisms and signaling pathways. In addition, it offers current and future perspectives on postbiotics in human health, addressing their role in managing insulin resistance, glucose metabolism, metabolic endotoxemia, and inflammation in type 2 diabetes. The text provides an in-depth analysis of the impact of postbiotics on non-alcoholic fatty liver disease (NAFLD), lipid profiles, and hypertension. In addition, the chapters:

1) Explore the promising concept of postbiotics and their potential beyond prebiotics and probiotics.

2) Examine the beneficial effects of postbiotics on cardiovascular health, cancer, diabetes, and other conditions.

3) Discuss the role of postbiotics in immune system modulation and inflammation-mediated metabolic disorders.

4) Cover the interaction of postbiotics with gut microbiota, highlighting molecular mechanisms and signaling pathways.

5) Analyze the current and future perspectives on postbiotics, including their impact on various metabolic disorders.

This book is a useful resource for researchers and students of pharmacology and biotechnology.

αž’αŸ†αž–αžΈβ€‹αž’αŸ’αž“αž€αž“αž·αž–αž“αŸ’αž’

Sumel Ashique has been working as an assistant professor at Department of Pharmaceutical Technology, Bharat Technology, West Bengal, India. He has 4 years of teaching experience. He has achieved 80 publications of International and national accredited reputed journals. He has knowledge in drug delivery, nanotechnology and targeted treatment strategy. He has also 5 granted patents from IP and Australia, with expertise in the field of targeted drug delivery, nanotechnology, gut-microbiome, postbiotics. Currently he is pursuing his PhD degree from Lovely Professional University, Punjab, India (NAAC A++) in the Pharmaceutical Science department.

Dr. Shakira Ghazanfar is a prominent microbiologist with a focus on probiotics. Since 2007, she has been a Senior Scientific Officer at the Pakistan Agricultural Research Council (PARC) and founded the Probiotic Development Lab in Islamabad. Dr. Ghazanfar earned her Ph.D. in Microbiology from Quaid-i-Azam University, specializing in gut microbial genomics. Her research has led to AI-driven probiotic products for humans and animals and the invention of a bioinformatics tool named Probio Predict. Currently, she is working on AI development in Pakistan and has published over 100 articles. She has also won several awards, including the Young Biotechnology Award in 2021, continuing to impact the industry with her groundbreaking research in microbial genomics and probiotic advancement.

Professor Dr. Naheed Mojgani, with a PhD in Microbiology (1997), heads the Human and Animal Probiotic Research Lab at the Razi Vaccine and Serum Research Institute in Iran. With over 70 peer-reviewed publications and extensive experience in infectious diseases, bacterial vaccines, and probiotics, she has made significant contributions to her field. Dr. Mojgani has received multiple awards, including the Outstanding Researcher Award and recognition from the Iranian Ministry of Education. She serves on several key committees and acts as a senior consultant, facilitating technology transfer for probiotic supplements. Dr. Mojgani has also supervised numerous students and organized workshops, enhancing education in her area of expertise.

Dr. Fernanda Maria Policarpo Tonelli, PhD, is an Assistant Professor at Federal University of SΓ£o JoΓ£o del Rei, DivinΓ³polis-MG, Brazil, where she teaches graduate and post-graduate students. She specializes in biotechnology/molecular biology and has been studying nanomaterials applications (such as delivery and environmental pollution remediation) as well as green synthesis protocols to produce bioactive nanoparticles, and the allelopathic potential of secondary metabolites from plants. The research projects developed by Dr. Tonelli have already resulted in 10 patent and 2 certificates of addition applications, 4 of them already analyzed and granted. She has published 15 books, authored 20 scientific articles and 57 book chapters with international publishers. Dr. Fernanda Tonelli has also dedicated herself to the promotion of science and technology through co-funding a non-governmental organization. She is a member of the editorial board and serves as a reviewer for many prestigious journals. Dr. Tonelli is active in groups of scientists that fight the gender gap in science. Her efforts as a researcher have been recognized with various awards, including For Women in Science Brazil and Under 30 Brazil.

αžœαžΆαž™αžαž˜αŸ’αž›αŸƒαžŸαŸ€αžœαž—αŸ…β€‹αž’αŸαž‘αž·αž…αžαŸ’αžšαžΌαž“αž·αž€αž“αŸαŸ‡

αž”αŸ’αžšαžΆαž”αŸ‹αž™αžΎαž„αž’αŸ†αž–αžΈαž€αžΆαžšαž™αž›αŸ‹αžƒαžΎαž‰αžšαž”αžŸαŸ‹αž’αŸ’αž“αž€αŸ”

αž’αžΆαž“β€‹αž–αŸαžαŸŒαž˜αžΆαž“

αž‘αžΌαžšαžŸαž–αŸ’αž‘αž†αŸ’αž›αžΆαžαžœαŸƒ αž“αž·αž„β€‹αžαŸαž”αŸ’αž›αŸαž
αžŠαŸ†αž‘αžΎαž„αž€αž˜αŸ’αž˜αžœαž·αž’αžΈ Google Play Books αžŸαž˜αŸ’αžšαžΆαž”αŸ‹ Android αž“αž·αž„ iPad/iPhone αŸ” αžœαžΆβ€‹αž’αŸ’αžœαžΎαžŸαž˜αž€αžΆαž›αž€αž˜αŸ’αž˜β€‹αžŠαŸ„αž™αžŸαŸ’αžœαŸαž™αž”αŸ’αžšαžœαžαŸ’αžαž·αž‡αžΆαž˜αž½αž™β€‹αž‚αžŽαž“αžΈβ€‹αžšαž”αžŸαŸ‹αž’αŸ’αž“αž€β€‹ αž“αž·αž„β€‹αž’αž“αž»αž‰αŸ’αž‰αžΆαžαž±αŸ’αž™β€‹αž’αŸ’αž“αž€αž’αžΆαž“αž–αŸαž›β€‹αž˜αžΆαž“αž’αŸŠαžΈαž“αž’αžΊαžŽαž·αž αž¬αž‚αŸ’αž˜αžΆαž“β€‹αž’αŸŠαžΈαž“αž’αžΊαžŽαž·αžβ€‹αž“αŸ…αž‚αŸ’αžšαž”αŸ‹αž‘αžΈαž€αž“αŸ’αž›αŸ‚αž„αŸ”
αž€αž»αŸ†αž–αŸ’αž™αžΌαž‘αŸαžšβ€‹αž™αž½αžšαžŠαŸƒ αž“αž·αž„αž€αž»αŸ†αž–αŸ’αž™αžΌαž‘αŸαžš
αž’αŸ’αž“αž€αž’αžΆαž…αžŸαŸ’αžŠαžΆαž”αŸ‹αžŸαŸ€αžœαž—αŸ…αž‡αžΆαžŸαŸ†αž‘αŸαž„αžŠαŸ‚αž›αž”αžΆαž“αž‘αž·αž‰αž“αŸ…αž€αŸ’αž“αž»αž„ Google Play αžŠαŸ„αž™αž”αŸ’αžšαžΎαž€αž˜αŸ’αž˜αžœαž·αž’αžΈαžšαž»αž€αžšαž€αžαžΆαž˜αž’αŸŠαžΈαž“αž’αžΊαžŽαž·αžαž€αŸ’αž“αž»αž„αž€αž»αŸ†αž–αŸ’αž™αžΌαž‘αŸαžšαžšαž”αžŸαŸ‹αž’αŸ’αž“αž€αŸ”
eReaders αž“αž·αž„β€‹αž§αž”αž€αžšαžŽαŸβ€‹αž•αŸ’αžŸαŸαž„β€‹αž‘αŸ€αž
αžŠαžΎαž˜αŸ’αž”αžΈαž’αžΆαž“αž“αŸ…αž›αžΎβ€‹αž§αž”αž€αžšαžŽαŸ e-ink αžŠαžΌαž…αž‡αžΆβ€‹αž§αž”αž€αžšαžŽαŸαž’αžΆαž“β€‹αžŸαŸ€αžœαž—αŸ…αž’αŸαž‘αž·αž…αžαŸ’αžšαžΌαž“αž·αž€ Kobo αž’αŸ’αž“αž€αž“αžΉαž„αžαŸ’αžšαžΌαžœβ€‹αž‘αžΆαž‰αž™αž€β€‹αž―αž€αžŸαžΆαžš αž αžΎαž™β€‹αž•αŸ’αž‘αŸαžšαžœαžΆαž‘αŸ…β€‹αž§αž”αž€αžšαžŽαŸβ€‹αžšαž”αžŸαŸ‹αž’αŸ’αž“αž€αŸ” αžŸαžΌαž˜αž’αž“αž»αžœαžαŸ’αžαžαžΆαž˜β€‹αž€αžΆαžšαžŽαŸ‚αž“αžΆαŸ†αž›αž˜αŸ’αž’αž·αžαžšαž”αžŸαŸ‹αž˜αž‡αŸ’αžˆαž˜αžŽαŸ’αžŒαž›αž‡αŸ†αž“αž½αž™ αžŠαžΎαž˜αŸ’αž”αžΈαž•αŸ’αž‘αŸαžšαž―αž€αžŸαžΆαžšβ€‹αž‘αŸ…αž§αž”αž€αžšαžŽαŸαž’αžΆαž“αžŸαŸ€αžœαž—αŸ…β€‹αž’αŸαž‘αž·αž…αžαŸ’αžšαžΌαž“αž·αž€αžŠαŸ‚αž›αžŸαŸ’αž‚αžΆαž›αŸ‹αŸ”